

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

Draft scope (pre-invite)

Remit/appraisal objective

To appraise the clinical and cost effectiveness of inotuzumab ozogamicin within its marketing authorisation for treating relapsed or refractory B-cell acute lymphoblastic leukaemia.

Background

Acute lymphoblastic leukaemia (ALL) is a cancer of lymphocyte-producing cells. Lymphocytes are white blood cells that are vital for the body's immune system. In ALL there is an excess production of immature lymphocyte-precursor cells, called lymphoblasts or blast cells, in the bone marrow. This affects the production of normal blood cells and there is a reduction in the numbers of red cells, white cells and platelets in the blood. ALL can be classified into 3 groups based on immunophenotyping: B-precursor ALL (also known as precursor-B-cell ALL), mature B-cell ALL and T-cell ALL. B-cell ALL is characterised by the presence of cytoplasmic immunoglobulins and CD10, CD19, CD22 and CD79a expression. A specific chromosomal abnormality known as the 'Philadelphia chromosome' is present in 20–30% of adults with ALL. The disease is described as Philadelphia-chromosome-positive if the abnormality is present, and Philadelphia-chromosome-negative if it is not present.

ALL is most common in children, adolescent and young adults, with 65% of cases diagnosed in people aged under 25 years. A second increase in incidence is observed in people aged over 60 years. In England, 820 people were diagnosed with ALL in 2013 and 240 people died from ALL in 2014.

The aim of treatment in ALL is to achieve a cure. Treatment for newly diagnosed ALL can take up to 3 years to complete and is generally divided into 3 phases; induction phase, consolidation and maintenance. Although selection of drugs, dose schedules and treatment duration may differ slightly between different subtypes of ALL, the basic treatment principles remain similar. During induction, newly diagnosed ALL is generally treated with chemotherapy combinations including prednisone, vincristine, anthracycline and asparaginase. NICE technology appraisal guidance 408 recommends pegaspargase (pegylated asparaginase), as part of antineoplastic combination therapy, as an option for untreated newly diagnosed acute lymphoblastic leukaemia in children, young people and adults. During the consolidation phase, intensified chemotherapy is used, which may include high dose methotrexate with mercaptopurine, high dose asparaginase, or a

repeat of the induction therapy. During the maintenance phase low dose chemotherapy is used, which typically consists of weekly methotrexate and daily mercaptopurine for an extended period of time to prevent relapse. For people with Philadelphia-chromosome-positive ALL, tyrosine kinase inhibitor therapy is added to these chemotherapy regimens. In adults with high risk acute ALL, stem cell transplantation and chemotherapy are considered equal first line treatment options.

Relapse or becoming refractory to initial treatment occurs in approximately 45% of people with newly diagnosed B-cell ALL. Although there is currently no standard of care for people with relapsed or refractory ALL, possible treatment options may include a combination chemotherapy based regimen of fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG), followed by stem cell transplantation where a suitable donor can be found, or best supportive care (including palliative care). Clofarabine is used outside its marketing authorisation in clinical practice in England through the Cancer Drugs Fund (CDF) for people with relapsed or refractory ALL ‘with intent to use the treatment to bridge to bone marrow transplant’ (at the time the scope was written; CDF transition funding remains in place until a commissioning decision from NHS England). Treatment of relapsed Philadelphia-chromosome-positive ALL includes re-induction therapy with tyrosine kinase inhibitors, such as imatinib or dasatinib, in addition to FLAG- or clofarabine-based chemotherapy.

The technology

Inotuzumab ozogamicin (Besponsa, Pfizer) is an antibody-drug conjugate of a monoclonal antibody. When inotuzumab ozogamicin binds to a CD22 antigen on a B-cell, it is absorbed into a malignant cell and leads to cell death.

Inotuzumab ozogamicin does not currently have marketing authorisation in the UK for ALL. It has been studied in clinical trials in adults with relapsed or refractory B-cell ALL with a CD22 expression.

Intervention(s)	Inotuzumab ozogamicin
Population(s)	Adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL)

<p>Comparators</p>	<p>For people who are able to take chemotherapy and have</p> <ul style="list-style-type: none"> • Philadelphia-chromosome-negative ALL: <ul style="list-style-type: none"> ○ fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG)-based combination chemotherapy ○ clofarabine-based combination chemotherapy (not appraised by NICE but funded via the CDF). • Philadelphia-chromosome-positive ALL: <ul style="list-style-type: none"> ○ tyrosine kinase inhibitors, in combination with FLAG- or clofarabine-based chemotherapy. <p>For people who are unable to take chemotherapy:</p> <ul style="list-style-type: none"> • best supportive care (including palliative care).
<p>Outcomes</p>	<p>The outcome measures to be considered include:</p> <ul style="list-style-type: none"> • overall survival • progression-free survival • treatment response rates (including haematologic responses) • time to and duration of response • adverse effects of treatment • health-related quality of life.
<p>Economic analysis</p>	<p>The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.</p> <p>The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.</p> <p>Costs will be considered from an NHS and Personal Social Services perspective.</p>

<p>Other considerations</p>	<p>If the evidence allows, a scenario analysis including stem cell transplant as a subsequent treatment after inotuzumab ozogamicin or its comparators will be considered. This should reflect the proportion of people who proceed to allogeneic stem cell transplant after each treatment, as well as the costs and quality-adjusted life year benefits of the procedure.</p> <p>Guidance will only be issued in accordance with the marketing authorisation. Where the wording of the therapeutic indication does not include specific treatment combinations, guidance will be issued only in the context of the evidence that has underpinned the marketing authorisation granted by the regulator.</p>
<p>Related NICE recommendations and NICE Pathways</p>	<p>Related Technology Appraisals:</p> <p>Pegaspargase for treating acute lymphoblastic leukaemia (2016). NICE technology appraisal TA408. Review date TBC.</p> <p>Terminated appraisals:</p> <p>Dasatinib for the treatment of acute lymphoblastic leukaemia (terminated appraisal) (2008).</p> <p>Appraisals in development:</p> <p>Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia NICE technology appraisals guidance [ID671]. Publication expected June 2017.</p> <p>Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia asparaginase (suspended appraisal) NICE technology appraisals guidance [ID864].</p> <p>Blinatumomab for previously treated B-precursor acute lymphoblastic leukaemia NICE technology appraisals guidance [ID804]. Publication date to be confirmed.</p> <p>Related Guidelines:</p> <p>Haematological cancers: improving outcomes (May 2016) NICE Guideline NG47. Review proposal date: September 2019.</p> <p>Suspected cancer: recognition and referral (June 2015). NICE guideline NG12.</p> <p>Improving outcomes in children and young people with cancer (August 2005). Cancer Service Guideline CGG7. Review decision: will be updated in July 2018.</p>

	<p>Related Quality Standards:</p> <p>Cancer services for children and young people (February 2014) NICE quality standard 55. Review date TBC.</p> <p>Related NICE Pathways:</p> <p>Blood and bone marrow cancers (2014) NICE Pathway (note that this pathway does not include acute lymphoblastic leukaemia).</p>
<p>Related National Policy</p>	<p>NHS England, Manual for prescribed specialised services 2016-2017, May 2016. Chapter 29 (Blood and marrow transplantation services (all ages)) and chapter 106 (Specialist cancer services for children and young people) https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/pss-manual-may16.pdf</p> <p>Department of Health, NHS Outcomes Framework 2016-2017, Apr 2016. Domains 1 and 2 https://www.gov.uk/government/publications/nhs-outcomes-framework-2016-to-2017</p> <p>Department of Health, Improving Outcomes: A strategy for cancer, fourth annual report, Dec 2014.</p> <p>Department of Health, Cancer commissioning guidance, Dec 2009.</p> <p>NHS England, National Cancer Drugs Fund List, Sep 2016.</p>

Questions for consultation

Have all relevant comparators for inotuzumab ozogamicin been included in the scope?

Which treatments are considered to be established clinical practice in the NHS for relapsed or refractory Philadelphia-chromosome-positive ALL?

- Are tyrosine kinase inhibitors used alone, or in combination with other treatments (such as FLAG- or clofarabine-based chemotherapy)?
- Which specific tyrosine kinase inhibitors are used routinely in clinical practice in the NHS for relapsed or refractory Philadelphia-chromosome-positive ALL?

How should best supportive care be defined?

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the proposed remit and scope may need changing in order to meet these aims. In particular, please tell us if the proposed remit and scope:

- could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which inotuzumab ozogamicin will be licensed;
- could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology;
- could have any adverse impact on people with a particular disability or disabilities.

References

Cancer Research UK (2014) [Acute lymphoblastic leukaemia \(ALL\) statistics](#), Accessed November 2016

Fielding AK, Richards SM, Chopra R et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL). *Blood* 2007(109), 944 – 50

Macmillan Cancer Support (2014) [Treatment overview for acute lymphoblastic leukaemia](#), Accessed November 2016